Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shuta Tomida

Showing results (71-80 of 169) with videos related to

Pageof 17
Sort By:
Springerplus|February 13, 2015
Performance of a novel KRAS mutation assay for formalin-fixed paraffin embedded tissues of colorectal cancerKazuko Sakai, Azusa Yoneshige, Akihiko Ito, et al.
Cancer Research|September 24, 2010
Regulation of DNA polymerase POLD4 influences genomic instability in lung cancerQin Miao Huang, Shuta Tomida, Yuji Masuda, et al.
Molecular Cancer Research : MCR|November 23, 2018
Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in <i>EGFR</i>-Mutant Non-Small Cell Lung Cancer CellsKei Namba, Kazuhiko Shien, Yuta Takahashi, et al.
Cancer Science|February 22, 2018
Antitumor activity of pan-HER inhibitors in HER2-positive gastric cancerTakahiro Yoshioka, Kazuhiko Shien, Kei Namba, et al.
Scientific Reports|February 2, 2018
MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinibKiichiro Ninomiya, Kadoaki Ohashi, Go Makimoto, et al.
The ISME Journal|April 8, 2015
The diversity and host interactions of Propionibacterium acnes bacteriophages on human skinJared Liu, Riceley Yan, Qiao Zhong, et al.
Cancer Medicine|May 10, 2022
Transcriptome of sessile serrated adenoma/polyps is associated with MSI-high colorectal cancer and decreased expression of CDX2Daisuke Ohki, Nobutake Yamamichi, Yoshiki Sakaguchi, et al.
International Journal of Oncology|June 18, 2015
EGFR and HER2 signals play a salvage role in MEK1-mutated gastric cancer after MEK inhibitionTakuro Mizukami, Yosuke Togashi, Shunsuke Sogabe, et al.
Oncology Letters|March 12, 2019
Anti-tumor effect of neratinib against lung cancer cells harboring <i>HER2</i> oncogene alterationsYusuke Ogoshi, Kazuhiko Shien, Takahiro Yoshioka, et al.
Oncology Letters|September 30, 2017
Elacridar, a third-generation ABCB1 inhibitor, overcomes resistance to docetaxel in non-small cell lung cancerHaiyang Chen, Kazuhiko Shien, Ken Suzawa, et al.
Pageof 17

Showing results (71-80 of 169) with videos related to

Sort By:
Pageof 17
Springerplus|February 13, 2015
Performance of a novel KRAS mutation assay for formalin-fixed paraffin embedded tissues of colorectal cancerKazuko Sakai, Azusa Yoneshige, Akihiko Ito, et al.
Cancer Research|September 24, 2010
Regulation of DNA polymerase POLD4 influences genomic instability in lung cancerQin Miao Huang, Shuta Tomida, Yuji Masuda, et al.
Molecular Cancer Research : MCR|November 23, 2018
Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in <i>EGFR</i>-Mutant Non-Small Cell Lung Cancer CellsKei Namba, Kazuhiko Shien, Yuta Takahashi, et al.
Cancer Science|February 22, 2018
Antitumor activity of pan-HER inhibitors in HER2-positive gastric cancerTakahiro Yoshioka, Kazuhiko Shien, Kei Namba, et al.
Scientific Reports|February 2, 2018
MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinibKiichiro Ninomiya, Kadoaki Ohashi, Go Makimoto, et al.
The ISME Journal|April 8, 2015
The diversity and host interactions of Propionibacterium acnes bacteriophages on human skinJared Liu, Riceley Yan, Qiao Zhong, et al.
Cancer Medicine|May 10, 2022
Transcriptome of sessile serrated adenoma/polyps is associated with MSI-high colorectal cancer and decreased expression of CDX2Daisuke Ohki, Nobutake Yamamichi, Yoshiki Sakaguchi, et al.
International Journal of Oncology|June 18, 2015
EGFR and HER2 signals play a salvage role in MEK1-mutated gastric cancer after MEK inhibitionTakuro Mizukami, Yosuke Togashi, Shunsuke Sogabe, et al.
Oncology Letters|March 12, 2019
Anti-tumor effect of neratinib against lung cancer cells harboring <i>HER2</i> oncogene alterationsYusuke Ogoshi, Kazuhiko Shien, Takahiro Yoshioka, et al.
Oncology Letters|September 30, 2017
Elacridar, a third-generation ABCB1 inhibitor, overcomes resistance to docetaxel in non-small cell lung cancerHaiyang Chen, Kazuhiko Shien, Ken Suzawa, et al.
Pageof 17